-
QuickStep ELISA Kits(Page)
QuickStep ELISA Kits | 90-Minute 1-Wash Assays | Assay Genie
Co-Inhibitory Checkpoints Beyond PD-1: CTLA-4, LAG-3 and TIM-3(Post)PD-1 gets the attention, but it is one brake among many — and the others do not work the same way. The co-inhibitory receptors are routinely drawn as interchangeable stop signs on a T cell. They are
Antibody Light Chains, Heavy Chains, Constant Regions & Tumour-Associated Antigens(Post)Immunology · Antibody BiologyAntibody Light Chains, Heavy Chains, Constant Regions & Tumour-Associated AntigensAn antibody’s specificity comes from its variable domains and its biological effect comes
TMB Incubation Time in ELISA: Why It Makes or Breaks Results(Post)Quick answer A researcher ran a high-sensitivity porcine insulin sandwich ELISA on EDTA plasma and saw main-run duplicate CVs as high as 29.6% (kit spec: intra-assay CV <8%) togethe
TIGIT, DNAM-1 and the CD155 Axis: Pathway, Function and Assays(Post)CD155 is read by four different receptors, and only one of them turns the killing programme on. The nectin and nectin-like ligands induced on stressed and transformed cells are simultaneously an acti
Mitotic Catastrophe Review(Post)Delving into the intricate world of Mitotic Catastrophe, this blog unveils its critical role in cell division and cancer therapy, offering insights into its mechanisms and potential treatments.
Exosomes: Tiny Messengers Revolutionizing Cancer Diagnosis and Therapy(Post)In the intricate world of cancer biology, a silent conversation is constantly unfolding between tumor cells and their environment. For decades, we viewed this dialogue as a one-way street, with cancer
Cobolimab: Unveiling TIM-3’s Role in Cancer Immunotherapy(Post)Quick Facts About CobolimabWhat is Cobolimab?Cobolimab is a monoclonal antibody that targets TIM-3, a checkpoint protein involved in immune regulation, especially in cancer and autoimmun
Onvatilimab: Redefining the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About OnvatilimabWhat is Onvatilimab?Onvatilimab is a monoclonal antibody targeting CD47, often referred to as the "don't eat me" signal, which is overexpressed on many cance
The Brain's Sentinels: How Microglia Shape Neuroinflammation in Disease(Post)The Brain's Sentinels: How Microglia Shape Neuroinflammation in Disease In the intricate landscape of the human brain, a silent, ever-watchful guardian stands ready to defend against injury and invas
Stabilité des réactifs ELISA : les règles à respecter au labo(Post)Stabilité des réactifs ELISA : les règles à respecter au labo Aliquotez, étiquetez et consignez systématiquement le numéro de lot et la date d’ouverture. Le reste de cet article détaille comment appl
Harnessing CD40 for Potent Anti-Tumor Immune Responses(Post)CD40, a member of the tumor necrosis factor receptor (TNFR) superfamily, plays a pivotal role in regulating immune responses, particularly in activating antigen-presenting cells (APCs) an
Cetuximab: A Revolutionary Drug in Cancer Therapy(Post)Quick Facts About CetuximabWhat is Cetuximab?Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), widely used in cancer therapy.How does Cetuximab wor
Labetuzumab: Revolutionizing Cancer Research with Targeted Therapies(Post)Quick Facts About LabetuzumabWhat is Labetuzumab?Labetuzumab is a monoclonal antibody targeting CEACAM5, a protein overexpressed in various cancers, primarily colorectal carcinoma.How do
Ulviprubart: A Breakthrough in Autoimmune Disease Treatment(Post)Quick Facts About UlviprubartWhat is Ulviprubart?Ulviprubart is an experimental complement inhibitor designed to modulate immune responses in autoimmune diseases.What is the mechanism of
Barrett’s Oesophagus to Oesophageal Adenocarcinoma – Review(Post)Oesophageal Adenocarcinoma is on the rise globally affecting more than 450,000 people worldwide (Pennathur, Gibson et al. 2013). Once diagnosed overall 5-year survival ranges from 15 % to 2
Natalizumab: Mechanism, Applications, and Emerging Research in Multiple Sclerosis and Crohn's Disease(Post)Quick Facts About NatalizumabWhat is Natalizumab?Natalizumab is a monoclonal antibody used to treat multiple sclerosis (MS) and Crohn's disease. It works by blocking immune cells from at
Zilovertamab: Unlocking the Potential of ROR1-Targeted Therapy(Post)Quick Facts About ZilovertamabWhat is Zilovertamab?Zilovertamab is a monoclonal antibody targeting ROR1, a receptor tyrosine kinase overexpressed in hematologic cancers and solid tumors.
Leukocytes : Basics to Diseases(Post)Only 1% of our blood is made up of white blood cells, but they have a significant impact. Alternatively referred to as leukocytes, white blood cells. We are shielded from disease and
Lorvotuzumab: Targeting CD56 in Cancer Research and Therapeutic Development(Post)Quick Facts About LorvotuzumabWhat is Lorvotuzumab?Lorvotuzumab is an antibody-drug conjugate (ADC) designed to target CD56, a surface antigen commonly overexpressed in neuroendocrine tu